The Telethon Foundation in Milan has been a longstanding supporter of research for genetic diseases, funding various projects for over three decades. However, in a surprising move, the charity has taken on a new role as a gene therapy company. This shift came about when the foundation acquired ownership of a drug developed by a small biotech company, which has been approved in Europe for the treatment of ADA-SCID, an ultra-rare immune disorder.
This decision by the Telethon Foundation to step into the realm of gene therapy is unprecedented for a nonprofit organization. By taking control of the gene therapy drug, the foundation aims to not only revive interest in the treatment but also establish a new model for delivering cutting-edge, one-time therapies in a financially sustainable manner.
The fact that a charity now holds the rights to this gene therapy medicine highlights the challenges facing the gene therapy field and the efforts of various groups, including nonprofits and academic researchers, to address the shortcomings of the current drug development system.
The move by the Telethon Foundation signifies a shift in how gene therapy treatments are developed and distributed. By taking on this responsibility, the foundation is pioneering a new approach to ensure that innovative therapies reach those in need, even in the face of financial and regulatory hurdles.
The integration of gene therapy into the work of a charity highlights the collaborative and innovative efforts being made to advance medical research and provide hope for patients with rare genetic disorders. This groundbreaking initiative by the Telethon Foundation serves as a beacon of hope for the future of gene therapy and the potential for nonprofits to drive meaningful change in the field of medicine.
